Innovent's Avastin Biosimilar Matches Efficacy of Original in Phase III Trial
publication date: Sep 19, 2019
Innovent Biologics of Suzhou announced its Avastin (bevacizumab) biosimilar produced similar results to the original drug in a double blind Phase III trial. Both drugs were administered together with paclitaxel/carboplatin as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). Innovent presented the data at the Chinese Society of Clinical Oncology (CSCO) earlier today. In late 2018, Innovent was approved to market its PD-1 drug, Tyvyt®, in China, the company's first launched product. More details....
Stock Symbol: (HK: 01801)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.